TAGS: Sustainability / Natural Cosmetics Skin Care
Willow Biosciences Inc. ("Willow"), announces the results of its in vitro analysis and the first to be reported topical clinical study on cannabigerol (“CBG”), in partnership with Signum Biosciences.
The Willow Study reports that biosynthetically produced CBG possesses a broad range of anti-inflammatory, antioxidant, and skin-protecting properties to help slow inflammation, aging, and boost skin barrier function.
Reduces Redness & Improves Barrier Function
Willow Study is one of the first to report the clinical effectiveness of topically applied CBG, demonstrating that a 0.1% CBG serum reduces inflammation, redness, and improves the skin barrier significantly better than a placebo.
Gene array analysis of CBG and cannabidiol (“CBD”) applied topically to a 3D human skin model demonstrates that CBG outperforms CBD, selectively targeting collagen, elastin, and other key skin health and hydration genes.
"Willow’s FutureGrown CBG continues to exhibit great promise as an exciting new skincare ingredient, we are excited to share the results of our in vitro and clinical work with our stakeholders and proud to have it published in a peer-reviewed scientific journal, the first of its kind for CBG. As the market for CBG and CBGA continues to develop, key studies such as this help to define the potential these ingredients have in the health and wellness space,” said Trevor Peters, Willow's president, and chief executive officer.
Moreover, in vitro studies in normal human epidermal keratinocytes (NHEKs) and human dermal fibroblasts (HDFs) show that CBG and CBD both possess strong antioxidant and anti-inflammatory properties, with CBG demonstrating equal if not better activity than CBD.
Source: Willow Biosciences